Alterhoment to

Page 1 of 5 FORM PTO 1449 APPLICATION NO. ATTY. DOCKET NO. INFORMATION DISCLOSURE STATEMENT 0125-0016D2 09/939.832 APPLICANT(S) McTigue et al. OCT 0 1 2007 FILING DATE GROUP August 28, 2001 1631 U.S. PATENT DOCUMENTS FILING DATE **EXAMINER** DOCUMENT DATE NAME CLASS SUB-CLASS INITIAL **NUMBER** AA1 4,966,849 10/30/90 Valee et al. 435 199 AB1 5,217,999 6/8/93 Levitzki, et. al. 514 613 AC1 5,302,606 4/12/94 Spada et al. 514 357 7/19/94 AD1 5,330,992 Eissenstat, et. al 514 312 FOREIGN PATENT DOCUMENTS **EXAMINER DOCUMENT** DATE **COUNTRY CLASS** SUB-CLASS **TRANSLATION** INITIAL **NUMBER** 1991 wo AE1 WO91/15495 □Yes □ No AFI WO92/20642 1992 wo □Yes □ No AG1 WO92/21660 1992 wo □Yes □ No AH1 WO94/03427 1991 wo □Yes □ No All 1994 wo WO94/10202 □Yes □ No wo AJ1 WO 98/49300 11/5/98 □Yes □ No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AK 1 Adamis et al., Arch. Ophthalmol., 114:66-71 (1996). Agouron Pharmaceuticals, Inc. "Agouron Solves Structure of Key Target for Drugs to AL 1 Block Angiogenesis: Human VEGF Receptor 2 Kinase", March 4, 1999. Bazenet et al., Mol. Cell. Biol., 16:6926-6936 (1996) AM 1 Borgström et al, Cancer Res., 56:4032-4039 (1996) AN 1 Bourne, H.R., et al., Basic & Clinical Pharmacology, 3rd Edition (Katzung et al., eds), AO 1 Chapter 3, pages 9-22 (1987) Choudhury et al., FEBS Letters, 282(2):351-354 (May, 1991) AP 1 Dvorak et al., Am. J. Path., 146:1029-1039 (1995) 1 AQ AR DeVries et al., Science, 255:989-991 (1992) 1 AS Dougher-Vermazen et al., Biochem. Biophys. Res. Comm., 205:728-738 (1994)

EXAMINER DATE CONSIDERED 81-03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.